Infanrix-Ipv

Pertussis Filamentous Haemagglutinin Adsorbed On Aluminium Hydroxide, Hydrated, Pertussis Toxoid Ads, the active ingredient in Infanrix-Ipv, is a vaccine presented as an injectable formulation for intramuscular use. It induces active immunity to prevent diphtheria, tetanus, pertussis (whooping cough) and poliomyelitis in infants and children.

GNH USA supplies Infanrix-Ipv as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Infanrix-Ipv is a combination vaccine that targets bacterial and viral agents responsible for several serious childhood diseases. - Diphtheria: induces protective immunity against Corynebacterium diphtheriae. - Tetanus: stimulates antibodies that neutralize tetanus toxin. - Pertussis (whooping cough): generates immunity to pertussis antigens, reducing disease severity. - Poliomyelitis: elicits antibodies that prevent infection by poliovirus strains.

Common Side Effects: - Pain, redness or swelling at the injection site. - Low‑grade fever within 24–48 hours. - Irritability or fussiness in infants. - Mild headache or fatigue. - Transient loss of appetite.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) with difficulty breathing. - High fever persisting more than 48 hours. - Seizures (rare febrile convulsions). - Persistent crying or inconsolable distress. - Neurological symptoms such as weakness or paralysis. - Signs of Guillain‑Barré syndrome.

Infanrix-Ipv should be administered by a qualified healthcare professional following national immunisation schedules. - Contraindication: known severe allergy to any vaccine component. - Caution: postpone vaccination if the child has a moderate or severe acute illness. - Monitor: observe the patient for at least 15 minutes after injection for immediate reactions. - Pregnancy: vaccine is not indicated for use during pregnancy; consult a physician. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vaccines generally have limited drug‑drug interactions, but certain conditions may modify immune response. Major Interactions (Avoid): - Live bacterial or viral vaccines administered concurrently. - Immunoglobulin therapy given within 2 weeks of vaccination. - High‑dose corticosteroids started within 2 weeks before or after vaccination. Moderate Interactions (Monitor Closely): - Immunosuppressive agents (e.g., chemotherapy) may reduce vaccine efficacy. - Antipyretics taken prophylactically may mask fever response. - Antihistamines may lessen local allergic signs but do not prevent serious reactions.